 Individuals with genotypes associated with low CYP2D6 activity poor metabolizers are unable to convert sufficient amounts of codeine or tramadol to their active metabolites and may fail to derive sufficient pain relief. At the opposite extreme, individuals with genotypes associated with increased CYP2D6 activity ultra-rapid metabolizers are at risk for serious toxicity with usual codeine or tramadol doses. 